DOI QR코드

DOI QR Code

Clinical and Hematologic Characteristics of Temporomandibular Disorders Patients

  • Park, Seo Eun (Department of Oral Medicine and Oral Diagnosis, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Kim, Ji Rak (Department of Dentistry and Oral Medicine, School of Medicine, Catholic University of Daegu) ;
  • Jo, Jung Hwan (Department of Oral Medicine, Seoul National University Dental Hospital) ;
  • Park, Ji Woon (Department of Oral Medicine and Oral Diagnosis, School of Dentistry and Dental Research Institute, Seoul National University)
  • Received : 2018.05.31
  • Accepted : 2018.06.22
  • Published : 2018.06.30

Abstract

Purpose: The aim of this study was to evaluate the possibility of utilizing blood tests for the diagnosis of temporomandibular disorders (TMDs) by investigating the hematologic characteristics of TMD patients according to the main source and level of TMD pain and analyzing their interrelationship. Methods: Clinical examination following the research diagnostic criteria for TMD and hematological and psychological evaluations were conducted in 357 TMD patients. Patients were divided into groups according to the main source of pain (myogenous, arthrogenous, and combined pain) and the degree of pain according to the graded chronic pain scale (GCPS). Hematological differences among the groups were statistically analyzed. Results: The C-reactive protein (CRP) level was significantly higher in the arthrogenous pain group compared to the combined pain group (p=0.032). There was no significant difference according to the GCPS classification. There were significant correlations between some of the TMD pain indices and the hematologic indices, and also between the psychological indices and the hematologic indices. Conclusions: This study suggests the possibility of applying blood tests to the diagnosis, treatment and prevention of TMD. Further research should be conducted focusing on the role of CRP in TMD pain with more refined methodology and a longitudinal study design.

Keywords

References

  1. Akturk S, Buyukavci R. Evaluation of blood neutrophil-lymphocyte ratio and platelet distribution width as inflammatory markers in patients with fibromyalgia. Clin Rheumatol 2017;36:1885-1889. https://doi.org/10.1007/s10067-017-3647-0
  2. de Leeuw R, Klasser GD; American Academy of Orofacial Pain. Orofacial pain: guidelines for assessment, diagnosis, and management. 5th ed. Chicago, IL: Quintessence Publishing; 2013. pp.127-186.
  3. Dworkin SF, Huggins KH, LeResche L, et al. Epidemiology of signs and symptoms in temporomandibular disorders: clinical signs in cases and controls. J Am Dent Assoc 1990;120:273-281. https://doi.org/10.14219/jada.archive.1990.0043
  4. Barros Vde M, Seraidarian PI, Côrtes MI, de Paula LV. The impact of orofacial pain on the quality of life of patients with temporomandibular disorder. J Orofac Pain 2009;23:28-37.
  5. Sasidharan PK, Bindya M, Sajeeth Kumar KG. Hematological manifestations of SLE at initial presentation: is it underestimated? ISRN Hematol 2012;2012:961872.
  6. Blaes F, Schmitz K, Tschernatsch M, et al. Autoimmune etiology of complex regional pain syndrome (M. Sudeck). Neurology 2004;63:1734-1736. https://doi.org/10.1212/01.WNL.0000143066.58498.BA
  7. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6:301-355.
  8. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992;50:133-149. https://doi.org/10.1016/0304-3959(92)90154-4
  9. Derogatis LR, Cleary PA. Confirmation of the dimensional structure of the SCL-90: a study in construct validation. J Clin Psychol 1977;33:981-989. https://doi.org/10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0
  10. Maixner W, Fillingim R, Booker D, Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain 1995;63:341-351. https://doi.org/10.1016/0304-3959(95)00068-2
  11. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-48490. https://doi.org/10.1074/jbc.R400025200
  12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardio- vascular disease in women. N Engl J Med 2000;342:836-843. https://doi.org/10.1056/NEJM200003233421202
  13. Ridker PM. C-reactive protein and the prediction of cardio- vascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129-2138. https://doi.org/10.1016/j.jacc.2007.02.052
  14. Ridker PM. Clinical application of C-reactive protein for car- diovascular disease detection and prevention. Circulation 2003;107:363-369. https://doi.org/10.1161/01.CIR.0000053730.47739.3C
  15. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-665. https://doi.org/10.1097/00054725-200409000-00026
  16. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, Garcia- Porrua C, Testa A, Llorca J. High-grade C-reactive protein eleva- tion correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005;32:1219-1223.
  17. Thorand B, Löwel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-99. https://doi.org/10.1001/archinte.163.1.93
  18. Okeson JP. Management of temporomandibular disorders and occlusion-E-Book. 7th ed. Edinburgh: Mosby Elsevier; 2014.
  19. Lee YC, Lu B, Bathon JM, et al. Pain sensitivity and pain reactiv- ity in osteoarthritis. Arthritis Care Res (Hoboken) 2011;63:320- 327.
  20. Spector TD, Hart DJ, Nandra D, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723-727. https://doi.org/10.1002/art.1780400419
  21. Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002;10:595-601. https://doi.org/10.1053/joca.2002.0800
  22. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 2005;44:7-16. https://doi.org/10.1093/rheumatology/keh344
  23. Kubota E, Kubota T, Matsumoto J, Shibata T, Murakami K. Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease. J Oral Maxillofac Surg 1998;56:192-198. https://doi.org/10.1016/S0278-2391(98)90868-0
  24. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K. Inter- leukin 1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 1997;55:20-27; discussion 27-28. https://doi.org/10.1016/S0278-2391(97)90438-9
  25. Takahashi T, Nagai H, Seki H, Fukuda M. Relationship between joint effusion, joint pain, and protein levels in joint lavage fluid of patients with internal derangement and osteoarthritis of the temporomandibular joint. J Oral Maxillofac Surg 1999;57:1187-1193; discussion 1193-1194. https://doi.org/10.1016/S0278-2391(99)90483-4
  26. Emshoff R, Puffer P, Rudisch A, Gassner R. Temporomandibular joint pain: relationship to internal derangement type, osteoarthrosis, and synovial fluid mediator level of tumor necrosis factor-alpha. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:442-449. https://doi.org/10.1067/moe.2000.108801
  27. List T, Jensen RH. Temporomandibular disorders: old ideas and new concepts. Cephalalgia 2017;37:692-704. https://doi.org/10.1177/0333102416686302
  28. Schmidt BL, Milam SB, Caloss R. Future directions for pain re- search in oral and maxillofacial surgery: findings of the 2005 AAOMS Research Summit. J Oral Maxillofac Surg 2005;63:1410- 1417. https://doi.org/10.1016/j.joms.2005.07.003
  29. Tanaka E, Detamore MS, Mercuri LG. Degenerative disorders of the temporomandibular joint: etiology, diagnosis, and treatment. J Dent Res 2008;87:296-307. https://doi.org/10.1177/154405910808700406
  30. Pankratz S, Bittner S, Kehrel BE, et al. The inflammatory role of platelets: translational insights from experimental studies of autoimmune disorders. Int J Mol Sci 2016;17:E1723. https://doi.org/10.3390/ijms17101723
  31. Shafiee M, Tayefi M, Hassanian SM, et al. Depression and anxiety symptoms are associated with white blood cell count and red cell distribution width: a sex-stratified analysis in a population-based study. Psychoneuroendocrinology 2017;84:101-108. https://doi.org/10.1016/j.psyneuen.2017.06.021
  32. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16. https://doi.org/10.1056/NEJM199107043250103
  33. Kohler-Forsberg O, Buttenschon HN, Tansey KE, et al. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain Behav Immun 2017;62:344-350. https://doi.org/10.1016/j.bbi.2017.02.020
  34. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-186. https://doi.org/10.1097/PSY.0b013e3181907c1b
  35. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a populationbasedlongitudinal study. JAMA Psychiatry 2014;71:1121-1128. https://doi.org/10.1001/jamapsychiatry.2014.1332
  36. Tayefi M, Shafiee M, Kazemi-Bajestani SMR, et al. Depression and anxiety both associate with serum level of hs-CRP: a genderstratified analysis in a population-based study. Psychoneuroendocrinology 2017;81:63-69. https://doi.org/10.1016/j.psyneuen.2017.02.035